ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

GLP-1 Medications For Postpartum Weight Loss: Usage & Treatment Guide Released

OrderlyMeds has released a guide to GLP-1 medications and weight loss treatments for women, especially during the postpartum period.

-- In a recently released resource, OrderlyMeds highlights the role of GLP-1 medications in weight loss programs, including plans for women who have recently given birth. Individuals who are considering starting a GLP-1 treatment with compounded medications can also use the company’s included online dosage calculator for a general idea of their dosage requirements.

For more information, please visit https://orderlymeds.com/dosage-calculator/

Glucagon-like peptide-1 receptor agonists (GLP-1) are a class of medications that are often prescribed for type 2 diabetes, but they are becoming increasingly common in medically supervised weight loss programs, notes the Orderly Meds team. GLP-1 drugs mimic a hormone in the body that is responsible for feelings of satiation; this hormone also regulates blood sugar levels and slows down digestion, prolonging feelings of fullness after eating.

While GLP-1s are safe to use for most people, individuals with certain pre-existing health conditions, such as pancreatic cancer or thyroid issues, or who otherwise have a history of medical contraindications may not be eligible for treatment.

OrderlyMeds notes that pregnant women will also be disqualified, while those who have already given birth are not advised to begin GLP-1 treatments if they are currently breastfeeding. However, the company says that medications can be considered after the immediate postpartum recovery period by women who are not breastfeeding - meaning a treatment protocol can be started about six to twelve weeks after giving birth.

For women and other individuals considering weight loss treatment, OrderlyMeds offers medically supervised programs that can be carried out completely online, allowing patients to complete treatment from the comfort of their home. The platform operates nationwide, connecting patients with licensed healthcare professionals regardless of their location. Treatment plans consist of a combination of GLP-1 or GIP medications, nutritional guidance, and exercise regimens tailored to meet the individual’s personal health goals; the option of more cost-effective compounded GLP-1 and GIP medications is also available if deemed medically appropriate.

A satisfied patient said, “OrderlyMeds changed my life. I have lost 50 pounds, and because of that, I no longer have obstructive sleep apnea. I have more energy now, and I feel more confident. A GLP-1 medication is what made all the difference for me. I’m now the same size as I was in my early 20s.”

More information is available at https://orderlymeds.com/

Contact Info:
Name: Annie Dawson
Email: Send Email
Organization: OrderlyMeds
Address: 235 Ponce De Leon Pl Suite M347, Decatur, Georgia 30030, United States
Website: https://orderlymeds.com/

Source: PressCable

Release ID: 89185248

In case of encountering any inaccuracies, problems, or queries arising from the content shared in this press release that necessitate action, or if you require assistance with a press release takedown, we urge you to notify us at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be readily available to promptly address your concerns within 8 hours, resolving any identified issues diligently or guiding you through the necessary steps for removal. The provision of accurate and dependable information is our primary focus.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  207.91
-2.23 (-1.06%)
AAPL  254.12
+2.63 (1.05%)
AMD  204.44
+1.76 (0.87%)
BAC  48.30
+0.78 (1.65%)
GOOG  292.79
-6.23 (-2.08%)
META  596.00
-8.06 (-1.33%)
MSFT  373.57
-9.43 (-2.46%)
NVDA  175.68
+0.04 (0.02%)
ORCL  148.08
-6.26 (-4.06%)
TSLA  383.57
+2.72 (0.71%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.